HEK293 cells provide a defined overexpression background, while Raji cells provide a hematopoietic membrane context. Select the host that best matches the intended assay and keep the host background consistent when comparing candidates.

Soluble TL1A supports controlled ELISA, SPR, and BLI screening. Membrane-bound TL1A cell lines then confirm cell-surface recognition and reveal avidity or accessibility effects that may be missed in protein-only assays.

DR3 recognizes trimeric TL1A, so oligomeric state can change epitope presentation and apparent avidity. MALS-verified active-trimer TL1A is preferable when assembly state could affect kinetic or inhibition results.

Customers should confirm the expression system, isoform and sequence coverage, tag position, purity, glycosylation pattern, and binding to the intended FGF ligand. Mammalian glycosylation can make the apparent SDS-PAGE molecular weight higher than the calculated value. Endotoxin is especially relevant for downstream cell assays, while direct SPR or BLI ligand-binding data are more informative for biophysical studies. Lot-specific specifications should be checked before use.

The extracellular domain is appropriate for FGF binding, ligand-neutralizing antibodies, and receptor-blocking antibodies. ATP-competitive inhibitors, receptor autophosphorylation, and downstream MAPK or PI3K signaling require a kinase-domain reagent or cells expressing full-length FGFR1. Selecting the assay according to the drug’s site of action prevents extracellular binding from being misinterpreted as inhibition of intracellular kinase signaling.